Results
1 -
7 of
7
(Click
here to explore results)
- Natural products to drugs: natural product derived compounds in clinical trials. Mark S. Butler
, Nat. Prod. Rep.
, 2005
, 22
, 162
- Modifications, biological origin and antibacterial activity of naphthalenoid ansamycins. Natalia Skrzypczak, Piotr Przybylski
, Nat. Prod. Rep.
, 2022
, 39
, 1653
- Strategies towards the synthesis of anti-tuberculosis drugs. Haridas B. Rode, Dhanaji M. Lade, René Grée, Prathama S. Mainkar, Srivari Chandrasekhar
, Org. Biomol. Chem.
, 2019
, 17
, 5428
- Beyond the approved: target sites and inhibitors of bacterial RNA polymerase from bacteria and fungi. Susanne H. Kirsch, F. P. Jake Haeckl, Rolf Müller
, Nat. Prod. Rep.
, 2022
, 39
, 1226
- Recent advances in the synthesis of new benzothiazole based anti-tubercular compounds. Rakhi Yadav, Dilkhush Meena, Kavita Singh, Rajdeep Tyagi, Yogesh Yadav, Ram Sagar
, RSC Adv.
, 2023
, 13
, 21890
- Natural products to drugs: natural product-derived compounds in clinical trials. Mark S. Butler
, Nat. Prod. Rep.
, 2008
, 25
, 475
- Semi-synthetic zwitterionic rifamycins: a promising class of antibiotics; survey of their chemistry and biological activities. Krzysztof Bujnowski, Ludwik Synoradzki, Radosław C. Darłak, Thomas A. Zevaco, Eckhard Dinjus
, RSC Adv.
, 2016
, 6
, 114758